Stockscreener 앱 받기
113.91
0.28%
-0.32
시간 외 거래:
113.91
전일 마감가:
$114.23
열려 있는:
$111.92
하루 거래량:
212.32K
Relative Volume:
0.66
시가총액:
$1.62B
수익:
$1.30M
순이익/손실:
$-35.78M
주가수익비율:
-17.36
EPS:
-6.5624
순현금흐름:
$-22.82M
1주 성능:
-16.61%
1개월 성능:
+38.36%
6개월 성능:
+95.59%
1년 성능:
+312.57%
1일 변동 폭
$109.86
$116.34
1주일 범위
$109.86
$138.83
52주 변동 폭
$18.23
$151.18
Palvella Therapeutics Inc Stock (PVLA) Company Profile
명칭
Palvella Therapeutics Inc
전화
(484) 253-1461
주소
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
113.91 | 1.63B | 1.30M | -35.78M | -22.82M | -6.5624 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 개시 | Mizuho | Outperform |
| 2025-12-05 | 개시 | BTIG Research | Buy |
| 2025-12-04 | 개시 | Craig Hallum | Buy |
| 2025-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | 개시 | Oppenheimer | Outperform |
| 2025-08-06 | 개시 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-04-09 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-26 | 개시 | Stifel | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-20 | 개시 | Canaccord Genuity | Buy |
| 2025-02-05 | 개시 | TD Cowen | Buy |
| 2024-12-26 | 개시 | H.C. Wainwright | Buy |
| 2024-12-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-03-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 개시 | Evercore ISI | Outperform |
| 2018-03-19 | 개시 | Jefferies | Buy |
| 2018-01-16 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-30 | 개시 | Rodman & Renshaw | Buy |
| 2016-08-05 | 재개 | ROTH Capital | Buy |
| 2015-08-12 | 개시 | JMP Securities | Mkt Outperform |
| 2015-07-27 | 개시 | Oppenheimer | Outperform |
| 2015-07-22 | 개시 | ROTH Capital | Buy |
모두보기
Palvella Therapeutics Inc 주식(PVLA)의 최신 뉴스
Topical statins show promise for rare skin disease in new review - MSN
Clear Street initiates coverage of Palvella Therapeutics (PVLA) with buy recommendation - MSN
Fred Alger Management LLC Increases Stock Holdings in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella receives European patent for rapamycin gel formulation By Investing.com - Investing.com India
Palvella Therapeutics: A Potential First-In-Class Therapy In A Rare Dermatology Market - Seeking Alpha
Palvella Therapeutics stock price target maintained at $220 by Clear Street - Investing.com Nigeria
Palvella Therapeutics (NASDAQ:PVLA) Earns Buy Rating from Chardan Capital - MarketBeat
Palvella Therapeutics launches awareness campaign for rare lymphatic disease - MSN
Palvella Therapeutics stock price target maintained at $220 by Clear Street By Investing.com - Investing.com India
Palvella Therapeutics Launches Awareness Campaign for Rare Lymphatic Disease - MyChesCo
Palvella receives European patent for rapamycin gel formulation - Investing.com
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin - GlobeNewswire
First Light Asset Management LLC Buys New Holdings in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Apis Capital Advisors LLC Makes New Investment in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Suvretta Capital Management LLC Boosts Stock Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Shares Down 8.7%Should You Sell? - MarketBeat
Palvella launches disease awareness campaign for rare lymphatic condition - Investing.com Nigeria
Quarterly Earnings: Can Palvella Therapeutics Inc lead its sector in growth2026 Price Swings & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Chipmakers Recap: Can Palvella Therapeutics Inc deliver alphaQuarterly Market Summary & Low Drawdown Investment Ideas - baoquankhu1.vn
Palvella launches disease awareness campaign for rare lymphatic condition By Investing.com - Investing.com South Africa
Palvella Therapeutics stock rating maintained at Buy by Clear Street - Investing.com Nigeria
Palvella Therapeutics Launches "BEYOND mLM" Disease - GlobeNewswire
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Palvella Therapeutics Reports Q1 2025 Financials and Clinical Progress - MSN
Palvella Therapeutics Names Ashley Kline Chief Commercial Officer - MSN
Published on: 2026-03-07 20:09:49 - baoquankhu1.vn
Palvella Therapeutics Secures New U.S. Patent for QTORIN Rapamycin - MSN
Blue Owl Capital Holdings LP Reduces Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat
PVLA Stock Soars On Strong Phase 3 Results For Rare Vascular Disorder Treatment - Stocktwits
Aug Closing: Is Palvella Therapeutics Inc stock trending bullishJuly 2025 Final Week & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Royce & Associates LP Decreases Stock Holdings in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Short Interest Update - MarketBeat
Palvella Reports Phase 3 Success for QTORIN in Rare Skin Disorder - MyChesCo
Palvella therapeutics (PVLA) director buys $500k in stock By Investing.com - Investing.com Australia
Palvella Therapeutics raises $230M in upsized stock offering By Investing.com - Investing.com Canada
Palvella Therapeutics raises $230M in upsized stock offering - Investing.com Australia
Heron Elaine J, Palvella therapeutics director, buys $300,000 in shares - Investing.com UK
Heron Elaine J, Palvella therapeutics director, buys $300,000 in shares By Investing.com - Investing.com Canada
Palvella therapeutics (PVLA) director buys $500k in stock - Investing.com South Africa
Palvella Therapeutics (NASDAQ:PVLA) Director Elaine Heron Purchases 2,400 Shares - MarketBeat
Insider Buying: Palvella Therapeutics (NASDAQ:PVLA) Director Acquires 4,000 Shares of Stock - MarketBeat
Palvella Therapeutics Insider Bought Shares Worth $300,000, According to a Recent SEC Filing - marketscreener.com
Assessing Palvella Therapeutics (PVLA) Valuation After Strong Recent Returns And A High P/B Multiple - Yahoo Finance
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares - GlobeNewswire
LGND: 2025 Results & Focus on Qtorin - Yahoo Finance
Is Palvella Therapeutics (PVLA) Still Attractive After A 7x One-Year Surge In Price? - simplywall.st
PVLA PE Ratio & Valuation, Is PVLA Overvalued - Intellectia AI
Palvella Therapeutics Announces Underwritten Common Stock Offering - The Globe and Mail
Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up Following Analyst Upgrade - Defense World
Palvella Therapeutics Inc (PVLA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):